...
首页> 外文期刊>Expert review of neurotherapeutics >Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles
【24h】

Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles

机译:神经内分泌激素作为急性中风预后的生物标志物:克服主要障碍

获取原文
获取原文并翻译 | 示例

摘要

Stroke represents one of the major causes of disability and mortality worldwide and prediction of outcome represents a challenge for both clinicians and researchers. In the past years, many blood markers have been associated with stroke outcome but despite this evidence, no biomarker is routinely used in stroke management. In this review, we focus on markers of the neuroendocrine system, which represent potential candidates to be implemented in clinical practice. Moreover, we present a systematic review and literature-based meta-analysis for copeptin, a new biomarker of the hypothalamo-pituitary-adrenal axis that has shown additional predictive value over clinical information in a large prospective study. The meta-analysis of the included 7 studies, with more than 2000 patients, reinforced its association with poor outcome (pooled odds ratio: 2.474 [1.678-3.268]) and mortality (pooled OR: 2.569 [1.642-3.495]). We further review the current situation of the topic and next steps to implement these tools by clinicians.
机译:中风是全球致残和死亡的主要原因之一,对结果的预测对临床医生和研究人员均构成挑战。在过去的几年中,许多血液标志物已与中风预后相关,尽管有这些证据,但在中风管理中没有常规使用生物标志物。在这篇综述中,我们着重于神经内分泌系统的标志物,这些标志物代表了在临床实践中可能实施的潜在候选物。此外,我们对肽素进行了系统的综述和基于文献的荟萃分析,肽素是下丘脑-垂体-肾上腺轴的一种新的生物标志物,在一项大规模的前瞻性研究中显示出比临床信息更多的预测价值。纳入的7项研究的荟萃分析对2000多名患者进行了强化,表明其与不良预后(合并比值比:2.474 [1.678-3.268])和死亡率(合并OR:2.569 [1.642-3.495])相关。我们将进一步审查该主题的现状以及临床医生实施这些工具的后续步骤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号